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Abstract  
Background: Patients with Myeloproliferative Neoplasms - (MPN) have a high risk of thrombotic complications. Portal vein 
thrombosis is a severe complication, which in many cases, appears at the onset of the disease; the risk factors are related to the 
presence of qualitatively altered thrombocytes and leucocytes, leading to their activation and appearance of leukocytes-platelet-
aggregates; anomalies of portal vein endothelial cells are also implicated. The presence of JAK2V617F mutation increases the risk 
for splahnic thrombosis.  
Methods and results: We present three patients with portal vein thrombosis and Budd Chiari syndrome, who were further 
diagnosed with MPN– the thrombosis was the onset event of the disease.  
Conclusion: Patients were diagnosed with thrombosis of the portal vein before being diagnosed with MPN. Splenectomy 
was not associated with risk of thrombosis for the two cases in which it was performed; for one case, splenectomy was a therapeutic 
method to resolve portal hypertension. All patients had homozygous JAK2 mutation, which is associated in recent studies with 
increased risk of portal, mesenteric thrombosis. The high number of platelet was difficult to control for all patients. Bone marrow 
biopsy and determination of JAK status are valuable investigations for patients who have splenoportal thrombosis, with no apparent 
identifiable cause. 
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Background 
Splanchnic vein thrombosis is a rare 
complication that can occur in patients with hereditary or 
acquired thrombophilia, including chronic 
myeloproliferative syndromes or after splenectomy. 
Recently, a more frequent association of splanchnic 
thrombosis with chronic myeloproliferative syndromes 
(CMPD) JAK positive was reported. The diagnosis of 
latent forms of CMPD may be difficult when patients have 
a normal number of cells in the peripheral blood. We 
present three cases with splanchnic vein thrombosis in 
which bone marrow biopsy and molecular tests 
established the diagnosis - JAK positive CMPD. 
Case presentation 
Case 1 - A 53-year-old male with hereditary 
spherocytosis; the repeated hemolytic events imposed 
therapeutical splenectomy; between 2004 and 2008 the 
patient had frequent episodes of hemolysis and severe 
anemia. After splenectomy, platelet count increased to 2 
million/mmc and one month later, he presented extensive 
thrombosis in the portal territory, superior mesenteric vein 
and splenic vein, with small abdominal lymph nodes. He 
received treatment with low molecular weight heparin for 
2 months, followed by efficient oral anticoagulation. 
Platelet count remained over 1 million/mmc. We raised 
the suspicion of MPN. Clinic examination revealed 
hepatomegaly (inferior limit 3-4 cm below ribs), without 
peripheral adenopathy. Laboratory: leukocytosis (WBC 
14,600/mmc) with normal differential, thrombocytosis 
(Platelets 523,000/mmc), Hemoglobin 12. 7g/dl. The 
peripheral blood smear showed an increased platelet 
number, platelet aggregates, and giant platelets; the 
leucocyte and erythrocyte features were normal. 
Biochemistry showed hepatic cytolysis, low serum iron, Journal of Medicine and Life Vol. 4, No. 1, January‐March 2011 
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increased bilirubin (direct fraction). Serology was negative 
for HBV, HCV and HIV. We performed a bone marrow 
trephine biopsy which revealed moderate megakaryocytic 
hyperplasia – with giant hyperlobulated megakaryocytes, 
dispersed and in small perivascular groups (Figure 1, a 
and b); 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gomori stain showed a diffuse densification in 
the reticulin system, with a fine structure (MF=1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum erythropoietin was normal – 20U/ml. We 
performed testing for JAK2V617F mutation – homozygote 
status was present. The diagnosis was: unclassifiable 
chronic myeloproliferative neoplasm, JAK positive 
homozygous, associated with hereditary spherocytosis 
and portal hypertension (due to portal vein thrombosis). 
To assess the severity of portal hypertension and to 
highlight other areas of extramedullary hematopoiesis we 
performed upper abdominal endoscopy, which revealed 
severe esophageal mycosis, without lesions on the 
stomach. Abdominal ultrasound scan - right lobe of liver 
moderately increased - 185 mm, with normal structure, 
presence of portal hypertension (12 mm the caliber of 
splenoportal vein). CT scan revealed small lymph nodes 
above and below the diaphragm. The patient received 
treatment with Hydrea 1gr/day associated with oral 
anticoagulant (Sintrom) according to INR value. We also 
took into consideration Anagrelid as a therapy option – it 
will be initiated soon. Interferon was excluded because 
the patient is depressive. Platelet count was maintained 
between 5-700,000/mmc. 
Case 2: A 29-year-old male with a history of 
hematemesis in the last 7 years, due to grade IV 
esophageal varices (endoscopy); abdominal CT scan: 
extended thrombosis of splenoportal axis. The 
splenectomy was performed, associated with shunts for 
decreasing portal hypertension. Three months after 
splenectomy, platelet count was over 800,000/mmc, the 
peripheral blood smear showed increased number of 
platelet with megathrombocytes and giant form, 
fragmented of megakaryocytes, large clumps of platelets. 
We raised the suspicion of MPN. Bone marrow trephine 
biopsy established diagnosis of ET and PCR exam – 
V617F mutation on JAK2 gene, homozygous pattern. The 
patient received treatment with Roferon 6 mill. daily. The 
platelet count maintained around 600,000-700,000/mmc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 (a and b): Bone marrow trephine biopsy: moderate 
megakaryocytic hyperplasia with giant hyperlobulated 
megakaryocytes (H&E stain, 1a - ob 10x; 1b – ob 40x) 
Fig. 2 Bone marrow trephine biopsy: diffuse, fine 
densification of the reticulin network (MF-1) (Gömöri stain, 
ob 10x)  
Fig. 3 Upper digestive endoscopy - patient with JAK positive 
MPN – esophageal varices 2nd degree. 
A 
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Case 3. A  54-year-old male, smoker, chronic 
alcohol consumer was referred to our department for 
rapid volume increase of the abdomen and diffuse 
abdominal pain. Objective exam: facial plethora, 
conjunctival hyperemia, jaundice, cyanosis of the nails, 
hepatosplenomegaly, ascitis. Laboratory screening 
showed pancytosis with erytrocytosis predominance (Hb 
20g/dl, Ht 62,6%, WBC 18000/mmc with neutrophilia, 1% 
Eos, 1% Baso; PLT 1000000/mmc), hepatocytolysis 
(AST, ALT – 15xN), cholestasis (GGT= 3xVN, ALKP= 
2xVN, BR= 3xVN), all coagulation times spontaneously 
prolonged, hypoalbuminemia. Bone marrow biopsy: 
hyperplasia on all lineages, highly suggestive pattern for 
chronic myeloproliferative disorder, without medullar 
fibrosis. Endogen erythropoietin – decreased (3mUI/ml). 
PCR exam – V617F mutation on JAK2 gene, 
homozygous pattern. Hematological diagnosis was 
Polycythemia Vera. 
For all three patients, we assessed the 
expression of several platelet markers by flowcytometry: 
CD61/CD41 – fibrinogen receptor, corresponding to 
GPIIb-IIIa – aggregation receptor, CD42a/CD42b – von 
Willebrand receptor, corresponding to GPIb-IX – adhesion 
receptor, CD62P – P-selectin – membranary activation 
receptor, CD63 – granulophysin – activation receptor. The 
results showed a state of platelet activation with increased 
expressions of CD62P and CD63. (Figure 4)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We also obtained a significant reduced 
expression of adhesion markers (CD42b more than the 
CD42a) for all patients, low expression of CD41 without 
any differences in CD61 expression. 
Platelet function was tested by platelet 
aggregation studies. We obtained normal response for 
ADP, collagen and epinephrine for these patients, 
although other patients with MPN had low response 
especially for epinephrine. The response for ristocetin 
was low for one of the patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Fig 4 The high expression of activation markers of platelets 
- CD62P and CD 63. 
A 
B 
Fig. 5 The low platelet aggregation for ristocetin and normal 
platelet aggregation for collagen in the CMPD JAK2 positive 
patient. 
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Discussion: Portal vein thrombosis or Budd 
Chiari Syndrome is a rare disorder; chronic 
myeloproliferative disorders neoplasms (MPN) represent 
the most common cause. Baxter et al identified the 
association of JAK2 mutation in 59% of patients with 
Budd-Chiari syndrome (BCS); Smalberg et al 
[Hematologica 2006 [1]] found a 41% prevalence of this 
mutation in BCS patients, on a group of 40 patients with 
primary non-malignant BCS. Thus, it is necessary to 
establish the importance of mutation detection in 
identifying the occult myeloproliferative syndromes [2]. In 
some cases, the presence of normal or slightly elevated 
leukocyte or platelet count can complicate the diagnosis. 
In the first two cases, the diagnosis was made after 
splenectomy, highlighted by the presence of an abnormal 
haematological picture, when a high number of platelets 
persisted for a long time and raised the suspicion of 
coexistence with MPN. Recent studies which included 
JAK2 positive patients, showed the presence of 
morphological and functional changes of endothelial cells 
corresponding port system. Circulating endothelial 
progenitor cells and liver endothelial cells may harbour 
the JAK2 mutation in patients with chronic 
myeloproliferative disorders, especially in patients who 
associate Budd Chiari syndrome, demonstrating the role 
of these cells in the pathogenesis of thrombosis, which 
may complicate the evolution of MPN. [3] The interaction 
between endothelial cells, white cells and platelets is 
achieved by complex mechanisms involving many 
receptors. These receptors may reveal the status of 
activated platelets and leukocytes (neutrophils and 
monocytes). They are in high number on the surface of 
platelet or leukocyte membrane and may explain the 
increased interfacing between endothelium and platelet or 
leukocyte. These receptors are CD11b, CD14, CD62P, 
CD63. P-selectin expression – basal or after stimulation – 
is increased in patients with MPN comparative positive 
JAK2 wild type allele, which shows the role of JAK2 in the 
modulation of activated status of platelets. P selectin has 
an important role in activating and selecting leukocyte at 
the site of endothelial lesion. In addition, JAK2 mutation is 
involved in activating the leukocyte and the coagulation 
cascade, in endothelial injury, in producing of leukocyte-
platelet aggregates.[3] The presence of leukocyte-platelet 
aggregates and microparticles (endothelial cell platelet 
aggregates) in blood circulation is more common in 
patients with ET and PV. The most common are 
CD11b/CD62P and CD11b/CD42b aggregates. These 
aggregates decrease in patients with MPN treated with 
Aspirin. The most sensitive method of detection is flow 
cytometry [3,4,5]. These explain thrombophilia and 
increased risk of thrombosis in patients with chronic 
myeloproliferative disorders, particularly those with JAK2 
mutation present. Increased risk of thrombosis in patients 
with MPN is due to resistance to activated C protein, 
which correlates with homozygous JAK2 status, with 
protrombotic role.[6] Monocytes from JAK2 positive 
patients with PV and especially ET have an increased 
capacity for synthesis of tissue factor. Increased level of 
tissue factor, associated with low levels of S protein, II 
factor, V factor and inhibitor of tissue factor, have been 
observed in patients with JAK2 positive MPN, explaining 
the tendency to thrombosis in these patients.[3] Also, 
leukocytosis and increased percentage of activated 
basophils have important role in thrombosis. [3,6]  
In patients considered for this study, an 
increased level of CD62P expression and CD 63 was 
observed, corresponding activated status of platelets. The 
expression of CD41 receptors was low and it was 
correlated with low platelet aggregation for ristocetin in 
one patient with JAK positive MPN. The expression of 
CD42a and CD 42b is low but platelet aggregation to 
collagen, ADP and epinephrine was normal, which shows 
changes both quantitative and especially qualitative of 
platelet receptor GPIIbIIIa. The platelet aggregation for 
ADP, collagen and epinephrine was more reduced in 
patients with MPN than controls, especially for 
epinephrine.  
Conclusions 
Patients with MPN JAK2 positive have a high 
incidence of splanchnic thrombosis. Determination of 
JAK2 mutation is useful for investigating the aetiology of 
portal vein thrombosis or Budd Chiari syndrome, if the 
aetiology of thrombosis is not obvious. This investigation 
may be followed by bone marrow biopsy in some cases 
heralded by haematological abnormalities.  
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Fig. 6 Normal platelet aggregation for ADP and epinephrin 
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